Cardiomyopathy is detected through a combination of symptom recognition, electrical recordings of the heart, imaging, blood tests, and sometimes genetic screening. No single test catches every type, so diagnosis typically involves layering several approaches. The specific path depends on whether you’re experiencing symptoms, have a family history, or are being screened as part of a sports physical.
Symptoms That Prompt Testing
Cardiomyopathy often develops silently. When symptoms do appear, the most common are shortness of breath (especially after meals or physical effort), dizziness, and fainting. These overlap with many other conditions, which is part of what makes cardiomyopathy tricky to catch early. Many people are diagnosed only after a routine test turns up something unexpected, or after a relative is diagnosed and the family undergoes screening.
Because symptoms alone can’t confirm cardiomyopathy, they mainly serve as the trigger for further investigation. If you’re noticing unexplained breathlessness during activities that didn’t used to wind you, or episodes of lightheadedness, those are worth flagging to a doctor so the right tests can be ordered.
What an ECG Can Reveal
An electrocardiogram is usually the first objective test. It’s quick, painless, and widely available. In hypertrophic cardiomyopathy (HCM), the most common inherited form, the ECG is abnormal in the vast majority of cases. Characteristic findings include abnormal Q-waves (detected in up to 53% of HCM patients, sometimes very early in the disease), deep inverted T-waves, and voltage patterns suggesting thickened heart muscle.
Certain ECG patterns point toward specific subtypes. Giant symmetric negative T-waves, for instance, suggest the thickening is concentrated at the apex of the heart. An isolated inverted T-wave in a single lead called aVL can sometimes be the only clue. Unusually high voltage may raise suspicion for storage diseases like Fabry disease, while the opposite pattern, low voltage despite obvious thickening on imaging, is a red flag for amyloidosis, a condition where abnormal proteins infiltrate the heart.
The ECG isn’t a standalone diagnostic tool. It flags abnormalities that need to be confirmed with imaging. But its accessibility makes it the most practical first step, and it’s the backbone of pre-participation screening in competitive athletes.
Echocardiography: The Primary Imaging Test
An echocardiogram, essentially an ultrasound of the heart, is the standard way to confirm a cardiomyopathy diagnosis. It shows the thickness of the heart walls, the size of the chambers, how well the heart contracts, and how blood flows through the valves. For HCM, the 2024 AHA/ACC guideline defines the diagnostic threshold as a maximum wall thickness of 15 mm or greater anywhere in the left ventricle, measured at the end of the heart’s filling phase, when no other cause of thickening (like longstanding high blood pressure) can explain it. A thickness of 13 to 14 mm can be enough for diagnosis if you have a family member with HCM or a confirmed genetic variant.
For dilated cardiomyopathy, the echocardiogram shows an enlarged, weakly contracting left ventricle. The key measurement here is the ejection fraction, the percentage of blood pumped out with each beat. A normal ejection fraction is roughly 55% to 70%. Values well below that range, combined with a stretched-out chamber, point toward dilated cardiomyopathy.
Echocardiography also picks up abnormal valve motion. One finding called systolic anterior motion, where the front leaflet of the mitral valve gets pulled toward the thickened wall during each heartbeat, is strongly suggestive of HCM and inconsistent with normal athletic adaptation.
Cardiac MRI for Deeper Detail
When echocardiography raises questions or doesn’t provide a clear answer, cardiac MRI steps in. It offers sharper images of the heart’s structure, but its real advantage is tissue characterization: the ability to see what’s happening inside the heart muscle itself.
The most important technique is called late gadolinium enhancement. After a contrast dye is injected, scarred or fibrotic areas of the heart retain the dye longer than healthy tissue, lighting up on the scan. This matters for two reasons. First, the pattern of scarring helps distinguish between different types of cardiomyopathy. Scarring that follows the distribution of a coronary artery suggests a prior heart attack, while patchy scarring at the junctions where the thickened wall meets the thin wall is more typical of HCM. In amyloidosis, the pattern may be diffuse or concentrated under the inner lining of the heart, and a transmural (full-thickness) pattern carries a worse prognosis than a more superficial one.
Second, the amount of scarring predicts risk. In HCM specifically, scarring that covers 15% or more of the heart muscle is associated with a significantly higher risk of dangerous heart rhythm disturbances. Both American and European guidelines now recommend that this level of scarring be factored into decisions about whether a patient needs a defibrillator, even when other conventional risk factors are low. No other imaging technique provides this kind of prognostic information as reliably.
Blood Tests That Support Diagnosis
Blood tests can’t diagnose cardiomyopathy on their own, but they help gauge how much stress the heart is under. The two most commonly measured markers are BNP and NT-proBNP, proteins released by heart muscle cells when they’re stretched or overworked.
In a non-emergency setting, the upper limit of normal for BNP is 35 pg/mL, and for NT-proBNP it’s 125 pg/mL. In someone arriving at an emergency room with acute breathlessness, a BNP below 100 pg/mL makes heart failure unlikely, while a level above 500 pg/mL strongly suggests cardiac dysfunction. NT-proBNP thresholds are age-adjusted: above 450 pg/mL for people under 50, above 900 pg/mL for those 50 to 75, and above 1,800 pg/mL for those over 75.
These values don’t pinpoint cardiomyopathy as the cause, but they help separate cardiac from non-cardiac causes of symptoms, and they’re useful for tracking disease progression over time.
Genetic Testing and Family Screening
Cardiomyopathy frequently runs in families. In HCM, genetic testing identifies a disease-causing variant in 40% to 50% of patients, most often in genes that encode the structural proteins of the heart’s contractile machinery. The two most commonly affected genes are MYBPC3 and MYH7.
Once a variant is found in one person (the “proband”), cascade testing becomes available for relatives. This is a targeted, single-site test that checks only for the specific variant already identified in the family, making it straightforward and relatively inexpensive. Current guidelines recommend offering this testing to relatives of all ages, including children, for HCM, dilated cardiomyopathy, and arrhythmogenic cardiomyopathy.
Having the variant doesn’t mean you’ll develop the disease, but the odds are substantial. Among relatives who carry a familial sarcomeric variant but show no signs of disease at the time of testing, about 50% go on to develop HCM over 15 years of follow-up. That’s why carriers need periodic imaging and clinical evaluation, even when they feel perfectly fine.
Telling Cardiomyopathy Apart From Athlete’s Heart
Regular intense training can thicken the heart walls and enlarge the chambers, mimicking cardiomyopathy on imaging. This is particularly common in endurance sports like rowing and cycling, where wall thickness can reach 13 mm or above. In contrast, power sports like weightlifting almost never push wall thickness past 12 mm. Female athletes rarely exceed 11 mm, and in a study of 600 elite women, none reached the 13 mm range that overlaps with HCM.
Several features help sort out the difference. An enlarged cavity (greater than 55 mm) favors athlete’s heart, since HCM typically has a small cavity, often under 45 mm. Normal relaxation patterns on Doppler imaging also favor athletic adaptation, as most HCM patients show impaired filling regardless of symptoms. And if there’s genuine uncertainty, a deconditioning trial can settle it: athletes with physiologic thickening typically see their wall thickness drop by 2 to 5 mm after about three months away from training. Pathologic thickening from HCM does not regress.
When a Heart Biopsy Is Needed
Endomyocardial biopsy, where a small sample of heart tissue is taken through a catheter, is reserved for situations where non-invasive testing can’t provide a definitive answer. The most common scenario is unexplained heart failure that develops rapidly, within two weeks, after other causes like coronary artery disease have been ruled out. It’s also used when heart failure lasting weeks to months is accompanied by dangerous arrhythmias and doesn’t respond to standard treatment.
Biopsy is particularly valuable for diagnosing infiltrative diseases. In amyloidosis, the tissue sample stained with a specific dye and viewed under polarized light produces a distinctive apple-green glow that is essentially diagnostic. It can also confirm arrhythmogenic right ventricular cardiomyopathy by showing the characteristic replacement of heart muscle with fatty and fibrous tissue, though most experts try non-invasive methods first and reserve biopsy for cases where doubt remains.
Screening for Athletes and Young People
Cardiomyopathy is a leading cause of sudden cardiac death in young athletes, and much of it is detectable before a catastrophic event. Pre-participation screening programs vary by country, but the most effective include a resting ECG alongside a health questionnaire. The Seattle Criteria and the International Criteria for Electrocardiographic Interpretation in Athletes provide standardized frameworks for reading these ECGs, helping clinicians distinguish the normal electrical changes caused by training from patterns that suggest underlying disease.
Adolescent athletes tend to have fewer abnormal ECG findings than adults, though high-intensity training can produce changes in the right side of the heart that require careful interpretation. When an ECG does flag something concerning, the next step is typically an echocardiogram or cardiac MRI to confirm or rule out structural disease. In one Canadian screening study of over 1,400 young competitive athletes, this approach identified one case of HCM along with several other cardiac conditions, while highlighting that relying on a physical exam and questionnaire alone produced a high number of false positives.